Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Clinical Trial to Assess the Impact of AferBio® on Quality of Life and Toxicity to Chemotherapy in Patients With NSCLC Beginning Second-line Palliative Mono-chemotherapy

NCT03469063 is registered in ClinicalTrials.gov with Barretos Cancer Hospital as lead sponsor.

NCT NCT03469063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03469063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Clinical Trial to Assess the Impact of AferBio® on Quality of Life and Toxicity to Chemotherapy in Patients With NSCLC Beginning Second-line Palliative Mono-chemotherapy
Lead sponsor
Barretos Cancer Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
June 28, 2018
Completion date
June 30, 2020
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug toxicity, infection, quality of life